Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia
Sponsor: ANRS, Emerging Infectious Diseases
Summary
The goal of this clinical trial is to evaluate the effectiveness of sofosbuvir/daclatasvir combination for children aged ≥ 6 years old and adolescents with active HCV infection in Cambodia
Official title: Pilot Therapeutic Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia
Key Details
Gender
All
Age Range
6 Years - 17 Years
Study Type
INTERVENTIONAL
Enrollment
21000
Start Date
2023-08-07
Completion Date
2026-01-31
Last Updated
2025-12-04
Healthy Volunteers
No
Conditions
Interventions
Sofosbuvir/Daclatasvir
Patients with a weight \> 25 kg will be treated with a sofosbuvir/daclatasvir combination for 12 weeks with adult dose (400/60 mg), children with a weight between 14 and 25 kg will be treated with the same sofosbuvir/daclatasvir combination with the half adult dose (200/30 mg) for 12 weeks.
Locations (4)
Battambang Provincial Hospital
Battambang, Cambodia
Kantha Bopha Hospital
Phnom Penh, Cambodia
National Pediatric Hospital
Phnom Penh, Cambodia
Jayavarman VII Hospital
Siem Reap, Cambodia